AZTR Stock — Azitra Inc: Cash, EV, Pipeline

Share price

$0.17

Market cap

$10.5M

Cash

$6.7M

Enterprise value

$3.8M

Balance sheet

Cash	$6.7M
Debt	$0.0M
Net cash	$6.7M
Enterprise value	$3.8M
Basic shares	60.6M shares
Fully diluted shares	69.4M shares
Fully diluted market cap	$11.8M
Cash per share	$0.11

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading AZTR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 26 - Apr 9	ATR04-484	Phase 2	EGFR Inhibitor-associated Rash	Q4 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ATR-12

Phase 1 · Active Modality: live biotherapeutic (engineered S. epidermidis, topical)

Aliases SE351, ATR-12-351

Target LEKTI (lympho-epithelial Kazal-type related inhibitor); replaces deficient LEKTI to counter dysregulated skin serine protease activity

Partnerships Fred Hutchinson Cancer Center: exclusive worldwide royalty-bearing license to SyMPL minicircle plasmid technology for genetic engineering (filing notes current candidates were engineered without SyMPL)

Indications

Netherton syndrome (Phase 1)

Status note Phase 1b first patient dosed August 2024; initial safety results reported H1 2025. In June 2026 the Company announced it paused enrollment for capital preservation; filing states it may resume development and has developed improved topical formulations and next-generation candidates.

ATR-04

Phase 1 · Active Modality: live biotherapeutic (engineered S. epidermidis, topical)

Aliases SE484, ATR-04-484

Target IL-36γ (Interleukin-36 gamma) inhibition

Partnerships Fred Hutchinson Cancer Center: exclusive worldwide royalty-bearing license to SyMPL minicircle plasmid technology for genetic engineering (filing notes current candidates were engineered without SyMPL)

Indications

EGFR inhibitor-associated papulopustular rash in cancer patients (Phase 1)

Catalysts

— around Q4 2026

Status note FDA IND clearance August 2024; Fast Track designation September 2024; first patient dosed in Phase 1/2 trial in Q3 2025. Engineered strain SE484 is D-alanine auxotrophic.

ATR-01

Preclinical · Active Modality: live biotherapeutic

Indications

not disclosed (Preclinical)

Status note Named as one of three lead product candidates; IND-enabling studies ongoing in 2026 per this filing. No indication or target stated.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ATR04-484
Lead indication	EGFR Inhibitor-associated Rash
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06830863	Phase 2	Recruiting	Sponsor	AZTR	—	EGFR Inhibitor-associated Rash	Q4 2026

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Azitra Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

AZTR — Azitra Inc

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials